NAYA Biosciences Strengthens Board with Industry Experts
NAYA Biosciences Strengthens Board with Industry Experts
NAYA Biosciences, a dedicated player in the realm of life sciences, is making a pivotal move by nominating five new candidates for their board of directors. This decision aligns with the company's goal of accelerating its focus on groundbreaking treatments in oncology and autoimmune diseases.
The New Board Candidates
The nominees, boasting extensive experience in biotechnology, are set to be approved at the upcoming shareholder meeting. Each candidate brings a wealth of knowledge pertinent to the evolving landscape of healthcare innovations.
Laurent Audoly, PhD
Dr. Laurent Audoly is a prominent figure in the industry, serving as the cofounder and CEO of PriveBio, a company dedicated to precision medicine. His rich background includes leadership roles in R&D at major pharmaceutical firms like Pfizer and Merck, where he was instrumental in securing eight drug approvals. Holding a PhD in Pharmacology and through his pivotal work, Dr. Audoly's insights will be invaluable to NAYA.
Melissa Fensterstock, MPhil, MBA
Melissa Fensterstock joins as a seasoned strategist advising the Material Impact Fund. Her experience as CEO of Lansdowne Labs and executive roles in higher education institutions have equipped her with a deep understanding of translating academic innovations into commercial success. With degrees from Harvard Business School and the University of Cambridge, Ms. Fensterstock will enhance NAYA's strategic direction.
Prakash Raman, PhD
Dr. Prakash Raman leads InduPro, Inc., a venture-focused on protein therapeutics. His previous role as Chief Business Development Officer at Flagship Pioneering and extensive tenure at Novartis underline his exceptional capability in navigating complex collaborations and product development. His experience will broaden NAYA's strategic insights.
Daniel Teper, PharmD, MBA
As the Founder and President of NAYA Biosciences, Dr. Teper's leadership has been crucial in driving the company forward. His past leadership roles in multiple biotech firms have refined his capacity to guide innovative projects through various commercial phases. Dr. Teper's pharmacy doctorate and MBA complement his experience in the biotech sphere.
Alexandra Urman, MPH
With a robust background as an analyst and an authority in healthcare innovation, Alexandra Urman currently serves as CEO of Aomics. Her career has spanned significant roles in cancer research and investments in genomics, solidifying her knowledge and leadership within the biotechnology field. Ms. Urman’s expertise will be an asset as NAYA continues to expand.
About NAYA Biosciences
NAYA Biosciences is committed to enhancing healthcare through innovative solutions for oncology, autoimmune diseases, and women's health. Their unique hub & spoke model allows for efficient resource allocation and development of therapies, promising high returns by combining commercial success with pioneering research.
NAYA’s Innovative Portfolio
The company is advancing several promising therapeutics. Notable among them is NY-303, a bifunctional antibody targeting hepatocellular carcinoma (HCC), which seeks to address the treatment gap for a significant percentage of patients. Others in development include bifunctional antibodies aimed at multiple myeloma and diverse solid tumors, leveraging cutting-edge science to improve patient outcomes.
Contact Information
For more information or inquiries regarding NAYA Biosciences, please reach out to:
Anna Baran-Djokovic
SVP, Investor Relations
+1-305-615-9162
anna@nayabiosciences.com
Frequently Asked Questions
What is the purpose of NAYA Biosciences' new board nominations?
The new board nominations aim to leverage extensive industry expertise to drive NAYA's growth in oncology and autoimmune disease treatments.
Who are the newly nominated board members?
The nominees include industry leaders like Laurent Audoly, Melissa Fensterstock, Prakash Raman, Daniel Teper, and Alexandra Urman, each bringing unique skills and backgrounds.
What is the focus of NAYA Biosciences?
NAYA Biosciences focuses on innovative treatments for oncology, autoimmune diseases, and women’s health, seeking to improve patient care through advanced therapeutics.
How does NAYA's model contribute to its success?
NAYA employs a hub & spoke model that effectively combines shared resources and strategic agility, optimizing the development and commercialization of its therapeutic assets.
Where can I find more information about NAYA Biosciences?
For more information, contact their investor relations at the email provided. Regular updates may also be available on their official website.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
